Cephalexin Powder for Suspension

Cephalexin Powder for Suspension

Form: Powder for Suspension

Strength: 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL

Reference Brands: Keflex(US & EU)

Category: Antibiotics

Cephalexin suspension is approved in the EU and US for pediatric and adult bacterial infections, including respiratory and urinary tract infections. In the EU, brands like Keflex are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on extensive clinical data, with many generics available. Both regions require comprehensive dossiers, including clinical trial results, production standards, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert support with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for cephalexin suspension, ensuring adherence to European and American standards for safe, effective antibiotic therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Fosfomycin Oral Sachets or Powder for Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details Get Enquiry
Fosfomycin IV

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.